Rajan Jain1, Laila Poisson, Jayant Narang, David Gutman2, Adam Flanders3, Carl Jaffe4, Brat Daniel2, Tom Mikkelsen
1Henry Ford Health System, Detroit, MI, United States; 2Emory University; 3Thomas Jefferson University Hospital; 4Boston University
The purpose of this study was to assess the utility of tumor blood volume measured using DSC T2* MR perfusion versus molecular sub-classification of glioblastoma for patient survival prediction. Our results show that rCBV measures do better than molecular mapping and sub-classes in predicting survival in this group of highly malignant and uniformly fatal tumors. Even though genomic mapping helps in better understanding of the molecular basis of tumor cell origin, aggressiveness and heterogeneity of glioblastoma, still non-invasive imaging biomarkers can be an important adjunct for patient prognosis.